Defeat Duchenne Canada Announce 2023-2024 Research Grants

Defeat Duchenne Canada, the country’s leader in Duchenne muscular dystrophy-funded research, is proud to announce that it will grant $880,320 toward five promising research projects this year – making the total awarded over its 29-year history $17.73M. The five new projects will enter a three-year agreement with the organization, joining six other research projects in years two and three of their funding.

 

Meet the researchers and hear the latest progress in Duchenne science.

Defeat Duchenne grant $17 million over 29-years to fund promising Duchenne research.

Read next...

CIHR logo

Emerging Leaders Webinar and Workshop Series from the CIHR-Institute of Musculoskeletal Health and Arthritis

The Emerging Leaders Series at CIHR-IMHA is designed to support learning and career development for a new generation of equitable and inclusive leaders in health research.

NMD4C launches 2024-2025 NNLS

NMD4C Launch Third Annual Training Series for Clinical Neuromuscular Fellows

The NMD4C Clinical Research Curriculum Development team is pleased to share that the third annual National Neuromuscular Lecture Series began this past August.

2025 clinical and research fellowships competition from NMD4C and MDC.

2025 NMD4C and MDC Neuromuscular Fellowship Funding Competition Opens

Together with MDC we are excited to announce the opening of our 2025 annual funding competition to award postdoctoral fellowships in NMD research, and clinical fellowship awards in neuromuscular medicine and electromyography! 

MDC-researchgrants-2025

MDC Translational Science and Clinical Research Grants Competition Opens for 2024-25

Muscular Dystrophy Canada’s annual Neuromuscular Research Grant Program invests in
projects related to the diagnosis, treatment, or clinical care of neuromuscular disorders.

RareKids-CAN logo

RareKids-CAN Offer Subsidized Services for Investigator-initiated Academic Clinical Trials

RareKids-CAN offers a range of subsidized services for investigator-initiated (academic-led) pediatric rare disease clinical trials.

Canada-reaches-100NBS_900px

100 percent of Canada is Now Screening Infants for Spinal Muscular Atrophy

We are excited to share that from August 20, 2024, all babies born in Canada can now be tested for spinal muscular atrophy (SMA), a potentially fatal neuromuscular disorder.